"Ivermectin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A mixture of mostly avermectin H2B1a (RN 71827-03-7) with some avermectin H2B1b (RN 70209-81-3), which are macrolides from STREPTOMYCES avermitilis. It binds glutamate-gated chloride channel to cause increased permeability and hyperpolarization of nerve and muscle cells. It also interacts with other CHLORIDE CHANNELS. It is a broad spectrum antiparasitic that is active against microfilariae of ONCHOCERCA VOLVULUS but not the adult form.
| Descriptor ID |
D007559
|
| MeSH Number(s) |
D02.540.576.500.997
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Ivermectin".
Below are MeSH descriptors whose meaning is more specific than "Ivermectin".
This graph shows the total number of publications written about "Ivermectin" by people in this website by year, and whether "Ivermectin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 0 | 2 | 2 |
| 2007 | 1 | 0 | 1 |
| 2011 | 0 | 2 | 2 |
| 2013 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
| 2022 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ivermectin" by people in Profiles.
-
Using Twitter data to understand public perceptions of approved versus off-label use for COVID-19-related medications. J Am Med Inform Assoc. 2022 09 12; 29(10):1668-1678.
-
Advancing a Human Onchocerciasis Vaccine From Antigen Discovery to Efficacy Studies Against Natural Infection of Cattle With Onchocerca ochengi. Front Cell Infect Microbiol. 2022; 12:869039.
-
Ivermectin in COVID-19: The Case for a Moratorium on Prescriptions. Ther Innov Regul Sci. 2022 05; 56(3):382-385.
-
Predicting the environmental suitability for onchocerciasis in Africa as an aid to elimination planning. PLoS Negl Trop Dis. 2021 07; 15(7):e0008824.
-
Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19. Am J Ther. 2021 04 22; 28(3):e299-e318.
-
COVID-19 in pediatric cancer patients in a resource-limited setting: National data from Peru. Pediatr Blood Cancer. 2021 02; 68(2):e28610.
-
Continuous high-dose ivermectin appears to be safe in patients with acute myelogenous leukemia and could inform clinical repurposing for COVID-19 infection. Leuk Lymphoma. 2020 10; 61(10):2536-2537.
-
In vivo loss-of-function screens identify KPNB1 as a new druggable oncogene in epithelial ovarian cancer. Proc Natl Acad Sci U S A. 2017 08 29; 114(35):E7301-E7310.
-
Ivermectin activates GIRK channels in a PIP2 -dependent, G?? -independent manner and an amino acid residue at the slide helix governs the activation. J Physiol. 2017 09 01; 595(17):5895-5912.
-
Anti-Wolbachia drug discovery and development: safe macrofilaricides for onchocerciasis and lymphatic filariasis. Parasitology. 2014 Jan; 141(1):119-27.